Moderna plans triple vaccine targeting flu, COVID and RSV
pharmaphorum
JULY 8, 2021
Buoyed by the success of its COVID-19 vaccine, Moderna has started a phase 1/2 trials of its mRNA-based shot for seasonal influenza, targeting four different flu strains. . Ultimately, the goal is to develop a shot that combines seasonal flu, COVID-19 and respiratory syncytial virus (RSV) protection with a single vaccine, said the biotech.
Let's personalize your content